🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. IVEMEND 150 mg powder for solution for infusion, Aprepitant Placebo Tablet, Aprepitant Teva 80 mg, harde capsules, NaCl I.V.

    AXIM BIOTECHNOLOGIES, INC.

    Delayed chemotherapy induced nausea and vomiting (CINV)

    phase 3 small molecule active

    1 trial

  2. IVEMEND 150 mg powder for solution for infusion, fosnetupitant chloride 260 mg/palonosetron 1.5 mg, fosnetupitant chloride 260 mg/palonosetron 2.5 mg, Ondansetrone Hikma 8 mg/4 ml Soluzione iniettabile, Sodium Chloride Injection BP 0.9% w/v

    Helsinn Birex Pharmaceuticals Ltd

    Chemotherapy-induced nausea and vomiting

    phase 3 small molecule active

    1 trial

  3. Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  4. Identical to kai-9531 solution for injection without active drug, KAI-9531, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  5. Iduronate-2-sulfatase enzyme replacement therapy

    Takeda

    Mucopolysaccharidosis II

    phase 3 mab completed

    1 trial

  6. IkT-001Pro, Placebo to match 100 mg IKT-001 tablets

    Inhibikase Therapeutics

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  7. Imatinib

    United Therapeutics Europe Ltd

    Myeloid Leukemia, Chronic, Chronic Phase

    phase 3 small molecule completed

    1 trial

  8. Imiquimod

    United Therapeutics Europe Ltd

    Cervical Intraepithelial Neoplasia

    phase 3 small molecule completed

    1 trial

  9. Imiquimod 5% cream

    Grace Therapeutics

    Superficial Basal Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  10. Imiquimod Cream, 3.75%

    Teva Pharma GmbH

    Actinic Keratosis

    phase 3 small molecule completed

    1 trial

  11. Immune Globulin 10% Intravenous Solution

    Vera Therapeutics

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  12. Immunoglobulins, Intravenous (Privigen)

    United Therapeutics Europe Ltd

    Encephalitis

    phase 3 small molecule completed

    1 trial

  13. Imnovid 3 mg hard capsules, DARZALEX 20 mg/mL concentrate for solution for infusion, Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 30 mg powder for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, Anitocabtagene autoleucel, Bortezomib Freseniu

    Lacuna Pharma Pty Ltd

    Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

    phase 3 small molecule active

    1 trial

  14. In-person Cognitive Behavioral Therapy of Insomnia

    United Therapeutics Europe Ltd

    Insomnia

    phase 3 other completed

    1 trial

  15. IncobotulinumtoxinA (XEOMIN®)

    Camp4 Therapeutics Corp

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  16. Induction Chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  17. Infigratinib

    BridgeBio Oncology Therapeutics

    Upper Tract Urothelial Carcinomas

    phase 3 small molecule terminated

    1 trial

  18. Infigratinib 0.25 mg/kg/day

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 3 small molecule completed

    1 trial

  19. Inhaled Human Insulin

    Nektar Therapeutics UK Limited

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  20. Inhaled Treprostinil

    United Therapeutics Europe Ltd

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  21. Inhaled treprostinil

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule active

    5 trials

  22. Inhaled treprostinil solution

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule terminated

    2 trials

  23. Intensive medical therapy

    Universal Integrated

    Myocardial Ischemia

    phase 3 other completed

    1 trial

  24. Intervention - a validated home BP monitor and support from the specialist nurse

    United Therapeutics Europe Ltd

    Stroke

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources